The discovery and synthesis of potential and novel antipsychotic coumarin derivatives, associated with potent dopamine D2, D3, and serotonin 5-HT1A and 5-HT2A receptor properties, are the focus of the present article. The most-promising derivative was 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-4-methyl-8-chloro-2H-chromen-2-one (17m). This derivative possesses unique pharmacological features, including high affinity for dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors. Moreover, it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity associated with chronic treatment) and hERG channels (to reduce the incidence of torsade des pointes). In animal models, compound 17m inhibited apomorphine-induced climbing behavior, MK-801-induced hyperactivity, and the conditioned avoidance response without observable catalepsy at the highest dose tested. Further, fewer preclinical adverse events were noted with 17m compared with risperidone in assays that measured prolactin secretion and weight gain. Acceptable pharmacokinetic properties were also noted with 17m. Taken together, 17m may constitute a novel class of drugs for the treatment of schizophrenia.

Novel benzoxazine (BOZ)/carboxylated graphene oxide (GO-COOH) composites were prepared via in situ intercalative polymerization.

A novel thermally sensitive shape memory (SM) hydrogel is prepared by block copoly-merization of a cationic surfactant monomer, dimethylhexadecyl[2-(dimethylamino)ethylmethacrylate]ammoniumbromide (C(16)DMAEMA), and acrylamide (AM) in the presence of α-cyclodextrin (α-CD) using N,N'-methylenebisacrylamide (MBA) as a crosslinker. XRD, solid state (13)C NMR, and DSC measurements show that the crystalline domains, induced by the hydrogen bonds between α-CDs threaded on the hydrophobic units of the polymer chains through the host-guest approach, can reversibly melt and crystallize at different temperatures. Rheological measurements show that both the elastic modulus G' and viscous modulus G'' drastically change due to the formation and dissolution of the crystalline domains. These thermo-sensitive crystalline domains serve as reversible physical crosslinks, endowing the hydrogel with excellent SM properties. Cyclic experiments show that the hydrogel can recover to almost 100% of the deformation in each cycle and can be reused several times.

BackgroundIt is important to develop novel antipsychotics that can effectively treat schizophrenia with minor side-effects. The aim of our work is to develop novel antipsychotics that act on dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors with low affinity for the serotonin 5-HT2C and H1 receptors, which can effectively cure positive symptoms, negative symptoms and cognitive impairment without the weight gain side-effect.Methodology/Principal FindingsA series of 2-substituted-5-thiopropylpiperazine (piperidine) -1,3,4-oxadiazoles derivatives have been synthesized and the target compounds were evaluated for binding affinities to D2, 5-HT1A and 5-HT2A receptors. Preliminary results indicated that compounds 14, 16 and 22 exhibited high affinities to D2, 5-HT1A and 5-HT2A receptors among these compounds. Further binding tests showed that compound 22 had high affinity for D3 receptor, and low affinity for serotonin 5-HT2C and H1 receptors. In addition, compound 22 inhibited apomorphine-induced climbing behavior and MK-801-induced hyperactivity with no extrapyramidal symptoms liability in mice. Moreover, compound 22 exhibited acceptable pharmacokinetic properties.Conclusions/SignificanceCompound 22 showed an atypical antipsychotic activity without liability for extrapyramidal symptoms. We anticipate compound 22 to be useful for developing a novel class of drug for the treatment of schizophrenia.

No abstract